A US scientific study showed that treatment with "Lecanemab", used for patients with early-stage Alzheimer's disease, is associated with changes in a group of biomarkers present in the blood, which may help develop methods to monitor patients' response to treatment and assess the progression of their condition.
For his part, the NeurologyLive website, specialized in neurology news, mentioned last week that the study was conducted by a research team from the Washington University School of Medicine in St. Louis, USA, led by researcher Roy Mo, and its results were recently published in "The Lancet Neurology" journal, specialized in neurology.
It added that the study included 197 patients who received the drug treatment, and the researchers analyzed 130 biomarkers in the blood, observing changes in indicators related to amyloid and tau proteins, whose accumulation is linked to the progression of Alzheimer's disease, as well as inflammation and nerve cell damage indicators.
The results indicated that monitoring these changes could contribute to the development of blood tests that help evaluate the treatment's impact and monitor disease-related changes, which may provide a less complex means of monitoring patients in the future and reduce reliance on expensive imaging tests.
"Lecanemab" is a targeted treatment for Alzheimer's disease, targeting the amyloid protein accumulated in the brain, and helps reduce its deposits, which may slow the decline in memory and cognitive abilities in patients in the early stages, but it does not cure the disease nor restore the mental abilities lost by the patient.
Alzheimer's is a progressive neurodegenerative disease that affects the brain, and is the most common cause of dementia, leading to a gradual decline in memory, thinking, and cognitive abilities, due to brain cell damage and loss of their functions, which affects the patient's ability to learn, communicate, and perform daily activities.
Source: Syrian Arab News Agency (SANA)
Comments (0)